Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel targeted therapies for patients with rare and difficult-to-treat cancers. The company’s research platform focuses on epigenetic regulators and cyclin-dependent kinases (CDKs), with the aim of modulating key pathways involved in tumor growth, survival, and metastasis. Salarius leverages proprietary drug discovery technologies to advance small-molecule inhibitors designed to address unmet medical needs in oncology.
The company’s lead asset, seclidemstat, is an oral lysine-specific demethylase 1 (LSD1) inhibitor being evaluated in multiple Phase 2 clinical trials for Ewing sarcoma and other solid tumors. In preclinical studies, seclidemstat has demonstrated the ability to impede tumor cell proliferation and reduce metastatic potential by altering the epigenetic landscape of cancer cells. Additionally, Salarius is developing fadraciclib, a potent CDK2/9 inhibitor targeting hematologic malignancies such as chronic lymphocytic leukemia and acute myeloid leukemia, with data supporting its role in disrupting transcriptional regulation in tumor cells.
Founded in 2017 and headquartered in Houston, Texas, Salarius Pharmaceuticals was established to harness cutting-edge science for the benefit of patients facing aggressive cancers. The company operates a lean organizational structure, partnering with leading academic institutions and Contract Research Organizations (CROs) to optimize clinical trial design and accelerate program timelines. This collaborative approach has enabled Salarius to advance multiple programs into the clinic while maintaining operational efficiency.
Salarius is led by a seasoned management team with extensive experience in drug development, regulatory affairs, and corporate strategy. Under the leadership of Chief Executive Officer Pete Hooper, the company has strengthened its clinical pipeline and expanded its strategic partnerships. Salarius intends to continue advancing its key programs through late-stage clinical development and, ultimately, to deliver novel therapeutic options to patients in the United States and select international markets.
AI Generated. May Contain Errors.
